{
    "clinical_study": {
        "@rank": "3325", 
        "arm_group": [
            {
                "arm_group_label": "MK-5172 + MK-8742 12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100mg/MK-8742 50mg fixed-dose combination tablets orally, once per day (QD) for 12 weeks"
            }, 
            {
                "arm_group_label": "MK-5172 + MK-8742 + RBV 12 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100mg/MK-8742 50mg fixed-dose combination tablets orally, QD for 12 weeks and RBV capsules, weight-based dose (800 to 1400 mg total daily dose), orally, twice per day (BID) for 12 weeks"
            }, 
            {
                "arm_group_label": "MK-5172 + MK-8742 16 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100mg/MK-8742 50mg fixed-dose combination tablets orally, QD for 16 weeks"
            }, 
            {
                "arm_group_label": "MK-5172 + MK-8742 + RBV 16 weeks", 
                "arm_group_type": "Experimental", 
                "description": "Participants receive MK-5172 100mg/MK-8742 50mg fixed-dose combination tablets orally, QD for 16 weeks and RBV capsules, weight-based dose (800 to 1400 mg total daily dose), orally, BID for 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an efficacy and safety study of MK-5172 in combination with MK-8742 with or without\n      ribavirin (RBV) in participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, 5,\n      or 6 infections who have failed prior therapy with pegylated interferon and RBV.  The\n      primary study hypothesis is that in at least one of the study arms, the percentage of\n      participants achieving  sustained viral response 12 weeks after the end of all study\n      treatment (SVR12) will be superior to 58%."
        }, 
        "brief_title": "Study of Efficacy and Safety of MK-5172 + MK-8742 With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, 5, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Documented chronic HCV GT1, GT4, GT5 or GT6 (with no evidence of non-typable or mixed\n             genotype) infection\n\n          -  Cirrhosis defined as liver biopsy showing METAVIR F4; or Fibroscan showing result\n             >12.5 kPa; or FibroSure\u00ae (Fibrotest\u00ae) score of >0.75 and an aspartate\n             aminotransferase (AST):platelet ratio index (APRI) of >2\n\n          -  Absence of cirrhosis defined as liver biopsy showing absence of cirrhosis; or\n             Fibroscan result of \u2264 12.5 kPa; or Fibrosure\u00ae (Fibrotest\u00ae) score of \u2264 0.48 and APRI \u2264\n             1\n\n          -  Previous HCV treatment status of peginterferon/RBV Null responder; or\n             peginterferon/RBV Partial responder; or peginterferon/RBV Treatment Relapse\n\n          -  For human immunodeficiency virus (HIV) co-infected participants: documented HIV-1\n             infection; currently na\u00efve to treatment with any antiretroviral therapy (ART) and\n             have no plans to initiate ART treatment while participating in this study; or be on\n             stable HIV ART for at least 8 weeks prior to study entry (dual nucleoside reverse\n             transcriptase inhibitor [NRTI] backbone of tenofovir or abacavir and either\n             emtricitabine or lamivudine plus raltegravir (or dolutegravir or rilpivirine);\n             cluster of differentiation 4 (CD4)+ T-cell count >200 cells/mm^3 at screening;\n             documented undetectable plasma HIV-1 ribonucleic acid (RNA) at least 8 weeks prior to\n             screening; participants not on ART, HIV RNA must be <50,000 copies/mL; never failed\n             more than 1 past HIV treatment regimen\n\n          -  Agree to use two acceptable methods of birth control from at least 2 weeks prior to\n             Day 1 and continue until at least 6 months after last dose of study drug, or longer\n             if dictated by local regulations; a male participant who is not (or whose partner is\n             not) of reproductive potential is eligible without requiring the use of contraception\n\n        Exclusion criteria:\n\n          -  Evidence of decompensated liver disease manifested by the presence of or history of\n             ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other\n             signs or symptoms of advanced liver disease\n\n          -  For participants with cirrhosis, participants who are Child-Pugh Class B or C or who\n             have a Pugh-Turcotte (CPT) score >6, must be excluded\n\n          -  Co-infected with hepatitis B virus\n\n          -  Has had previous direct-acting antiviral treatment\n\n          -  History of malignancy <=5 years prior except for adequately treated basal cell or\n             squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is\n             under evaluation for other active or suspected malignancy\n\n          -  Has cirrhosis and liver imaging showing evidence of hepatocellular carcinoma (HCC) or\n             is under evaluation for HCC\n\n          -  Taking or plans to take any HIV therapy that includes a ritonavir-boosted or\n             unboosted protease inhibitor, efavirenz or etravirine\n\n          -  Currently participating or has participated in a study with an investigational\n             compound within 30 days of signing informed consent and is not willing to refrain\n             from participating in another such study during the course of this study\n\n          -  Clinically-relevant drug or alcohol abuse within 12 months\n\n          -  Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from at\n             least 2 weeks prior to Day 1 and continue throughout treatment and follow up, or\n             longer if dictated by local regulations; or is a male whose female partner(s) is/are\n             pregnant\n\n          -  History of organ transplant (including hematopoietic stem cell transplants) other\n             than cornea and hair\n\n          -  Poor venous access\n\n          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption\n             disorders (e.g., celiac sprue disease)\n\n          -  Hemoglobinopathy, including, but not limited to, thalassemia major\n\n          -  Any medical condition requiring, or likely to require, chronic systemic\n             corticosteroids during the course of the trial\n\n          -  For participants with HIV, history of opportunistic infection in the preceding 6\n             months\n\n          -  For participants with HIV, use of HIV drugs other than a dual NRTI backbone of\n             tenofovir or abacavir and either emtricitabine or lamivudine plus raltegravir (or\n             dolutegravir or rilpivirine)\n\n          -  Evidence or history of chronic hepatitis not caused by HCV, including but not limited\n             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune\n             hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105701", 
            "org_study_id": "5172-068", 
            "secondary_id": "2014-000824-12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-5172 + MK-8742 12 weeks", 
                    "MK-5172 + MK-8742 + RBV 12 weeks", 
                    "MK-5172 + MK-8742 16 weeks", 
                    "MK-5172 + MK-8742 + RBV 16 weeks"
                ], 
                "description": "Fixed-dose combination tablet", 
                "intervention_name": "MK-5172 + MK-8742", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-5172 + MK-8742 + RBV 12 weeks", 
                    "MK-5172 + MK-8742 + RBV 16 weeks"
                ], 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 2, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, GT5, and GT6 Infection", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants achieving SVR12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after the end of all study treatment (up to 28 weeks)"
            }, 
            {
                "measure": "Number of participants experiencing adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 40 weeks"
            }, 
            {
                "measure": "Number of participants discontinuing study treatment due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 16 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105701"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants achieving SVR 24 weeks after the end of all treatment (SVR24)", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after the end of all study treatment (up to 40 weeks)"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}